Recent studies have converged on the convergence of GLP|GIP|GCGR activator therapies and dopamine neurotransmission. While GLP agonists are commonly employed for treating type 2 diabetes mellitus, their emerging consequences on reinforcement circuits, specifically governed by dopamine pathways, are attracting considerable attention. This report … Read More